$DVLT

Vivasor, Inc. sold $1.3M of DVLT

Vivasor, Inc. sold 2,535,083 shares of Datavault AI Inc. (DVLT) at $0.50 ($1.27M total) on 2026-05-07.

Original reporting
SEC EDGAR · Vivasor, Inc.
Published Jun 3, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVLT
Neutral
low confidence
Mentioned
$DVLT
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVLTNeutralLow
01

Why it matters

A disclosed open-market sale by a 10% owner can modestly affect sentiment, but it is not a fundamental catalyst by itself.

02

Market read

Traders may monitor for follow-on selling or changes in insider behavior, but the filing alone offers limited decision-making edge.

03

What to watch

Form 4 timing can lag; the sale date (2026-05-07) may already be priced, and insider sales are common even when long-term fundamentals remain unchanged.

Relevance 7/10Novelty 6/10Timing: After-hours/next-session read-through of a newly filed Form 4 (filed 2026-06-02; dated 2026-05-07).

Background

The article is an SEC EDGAR insider transaction disclosure (Form 4) for Datavault AI Inc. (DVLT).

Company-level read

Ticker impact

$DVLTNeutralLow confidence
Context

SEC Form 4 shows 10% owner Vivasor, Inc. sold 2,535,083 DVLT shares for ~$1.27M in an open-market transaction.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than catalyst-driven.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory). It does not state reasons for sale, and the article provides no new company fundamentals or guidance.

Market effects

Minimal—single-company insider sale without broader sector/regulatory context.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing; absence of a stated reason (and no 10b5-1 plan disclosed) limits inference.

Key entities

  • Datavault AI Inc.

    Subject of the Form 4 insider transaction; DVLT shares were sold by a 10% owner.

  • Vivasor, Inc.

    Reporter of the Form 4; sold 2,535,083 DVLT shares for ~$1.27M.

Related articles

$DVLTMed

Datavault AI Hit With Securities Lawsuit

Datavault AI Inc. (NASDAQ: DVLT) faces a new securities class action, according to DJS Law Group, alleging the company misled investors about operations, partnerships, and growth prospects. The proposed class period is Sept. 4, 2024 to Oct. 30, 2025. The claims stem largely from a Wolfpack Research report that preceded a ~19% one-day share drop. Lead plaintiff deadline is Oct. 5, 2026.

$DVLTMed

Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT

Pomerantz LLP said it filed a securities class action against Datavault AI Inc. (NASDAQ: DVLT) and certain officers in the Eastern District of Pennsylvania, covering purchases from Sept. 4, 2024 to Oct. 30, 2025. The suit alleges misleading statements about partnerships, trading activity, and compliance. After a Wolfpack Research report on Oct. 31, 2025, DVLT shares fell 19.44% to $2.03.

$DVLTMed

Datavault AI Expands Data Driven Outcome Healthcare

Datavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.

$MEDSMed

DataMEDS AI, Inc.: DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

DataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.